Early Combined Immunosuppression Treatment in Crohn’s Disease Found to Improve Disease Course

Early Combined Immunosuppression Treatment in Crohn’s Disease Found to Improve Disease Course
A new study recently published in the journal The Lancet revealed that early combined immunosuppression (ECI) treatment can improve the disease course in patients with Crohn’s disease. The study is entitled “Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial”, and was led by researchers at the Robarts Research Institute and the University of Western Ontario in Canada. Canada is known to have one of the highest rates in the world of patients with Crohn’s disease, a lifelong chronic inflammatory bowel disorder that can cause fever, fatigue, abdominal pain, diarrhea, malnutrition and weight loss. There is no cure for Crohn’s disease and its exact causes are unknown. Individuals with Crohn’s disease are more likely to be hospitalized, with approximately half of them requiring surgery. Crohn’s disease patients are also estimated to be 47% more likely to have a premature death. In the study, researchers conducted a trial called Randomized Evaluation of an Algorithm for Crohn’s Treatment (REACT, NCT01030809), and the goal was to assess the safety and efficacy of an ECI treatment in comparison to conventional treatment. The trial was conducted at 39 different locations in Canada and Belgium between March 2010 and October 2013, and enrolled 1,982 Crohn’s disease patients. Patients were randomly
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *